Extensive mucocutaneous, oesophageal and otic lichen planus secondary to nivolumab therapy by Ferguson, L et al.
Received: 17 September 2020 - Revised: 19 October 2020 - Accepted: 23 October 2020DOI: 10.1002/ski2.8
CA S E R E POR T
Extensive mucocutaneous, oesophageal and otic lichen
planus secondary to nivolumab therapy
L. Ferguson1 | B. Ho2 | J. Weir3 | N. Francis3 | K. West4 | B. Rathbone5 |
J. Larkin1 | K. Heelan1
1Royal Marsden Hospital NHS Trust, London,
UK
2Dermatology Department, St George's
University Hospitals NHS Foundation Trust,
London, UK
3Department of Histopathology, Imperial
College Healthcare NHS Trust, London, UK
4Histopathology Department, Leicester Royal
Infirmary, Leicester, UK
5Gastroenterology Department, Leicester
Royal Infirmary, Leicester, UK
Correspondence
Leila Ferguson, Skin Unit, Royal Marsden
Hospital NHS Trust, London, UK.
Email: leilaferguson@ymail.com
Abstract
We report a 73‐year‐old female with metastatic renal cell carcinoma who
developed a widespread lichenoid reaction following nivolumab treatment.
The timeline of the reaction strongly correlated with the nivolumab
treatment and subsequent cessation. Our patient had cutaneous, mucosal,
otic, ophthalmic and oesophageal involvement, demonstrating the poten-
tially extensive nature of lichenoid reactions to anti‐programmed cell death
receptor‐1 (anti‐PD1) therapies. Although lichenoid reactions to anti‐PD1
therapies are now well recognized, there have been no previous reports of
otic or oesophageal involvement in the literature. Although cutaneous
lichenoid reactions do not tend to be severe or treatment limiting, more
widespread systemic lichenoid reactions are challenging to manage,
particularly in the context of malignancy. This very unusual case highlights
the importance of considering involvement beyond the skin in all lichenoid
skin reactions.
1 | CASE REPORT
We report an extensive lichenoid reaction associated
with nivolumab therapy. Following a left humerus
pathological fracture, a 73‐year old female was diag-
nosed with metastatic renal clear cell carcinoma. The
fracture site was resected and treated with radio-
therapy. Whole‐body magnetic resonance imaging
identified bony lesions and computerised tomography
staging at 3 months revealed disease progression with
new bone involvement. Initial management with tyro-
sine kinase inhibitor (sunitinib) was complicated by
diarrhoea and cardiac failure necessitating discontinu-
ation. We started her on nivolumab, a programmed cell
death receptor‐1 (PD‐1) inhibitor.
By inhibiting PD‐1, nivolumab facilitates T‐cell
activation, which potentiates an immune response to
tumour cells and is recommended for treatment of
several malignancies. Excess T‐cell activation may
induce T‐cell‐mediated diseases. Most immune‐related
adverse events (irAEs) improve or resolve with corti-
costeroids and treatment modifications; however, life‐
threatening irAEs have been reported.
After the initiation of nivolumab, a good response
was noted on imaging over 12 months. She developed
irAEs including arthritis, mild colitis and pneumonitis at
6 months. Grade 3 colitis at 12 months required
intravenous methylprednisolone followed by prednis-
olone 1 mg/kg and temporary cessation of nivolumab.
Eighteen months after commencing nivolumab,
she developed vulval pain, painful oral ulceration,
dysphagia, a widespread pruritic rash and weight loss.
Examination of the oral mucosa revealed Wickham's
striae and apical erythema of the gingiva (Figure 1a).
Genital examination demonstrated symmetrical
severe erythema and tenderness of the labia minora
(Figure 1b). A widespread purple, papular rash affecting
the arms, back, flanks and lower abdomen is shown
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(Figure 1c). A skin biopsy from the abdomen showed
lichenoid inflammation with dyskeratotic keratinocytes
and eosinophils, consistent with a lichenoid reaction
(Figure 2a).
Cutaneous adverse events (AEs) to PD‐1 inhibitors,
including lichen planus (LP), are increasingly reported.1
The incidence of cutaneous AE varies (8.7%1–49%2).
Incidence of irAEs increases with duration of treat-
ment,2 but the onset of LP after treatment initiation
varies (2 weeks3 to months). LP, a T‐cell‐mediated
chronic inflammatory disease, may be a new phe-
nomenon, or represent a recurrence of quiescent LP.3
Classic LP is commonly described, but hypertrophic3
and bullous LP4 are also reported.
In our patient, initial treatment with super‐potent
topical steroids and betamethasone mouthwashes
yielded a partial response. A subsequent flare of colitis
necessitated the use of systemic steroids and the
cessation of nivolumab. This led to a resolution of both
her rash and mucositis. As prednisolone was weaned,
the gingival and vulvovaginal symptoms recurred. A
vulval biopsy confirmed a lichenoid reaction (Figure 2b)
and demonstrated a negative direct immunofluores-
cence. Dysphagia and hoarseness developed. Oeso-
phageal biopsies demonstrated inflammation of the
squamous mucosa consistent with LP (Figure 2c). A
slow wean of oral prednisolone 0.5 mg/kg ensued with
continued topical corticosteroid application. Current
maintenance is with low‐dose acitretin (10 mg daily),
topical corticosteroids as required and fluticasone
propionate pharyngeal spray. Recent development of
aural symptoms (scaling, debris, pruritis and otorrhoea)
due to lichenoid inflammation of the external auditory
canal improved with topical tacrolimus drops.
Ophthalmological symptoms (punctual occlusion)
required hot compress, massage and topical steroids.
Idiopathic LP may affect skin or mucous membranes
including vagina, vulva, oral cavity, ear canals, oesoph-
agus and lacrimal ducts. Anti‐PD‐1‐induced mucous‐
membrane LP was considered rare (1/14 patients),2 but
recent case series suggest oral reactions are under‐
recognized or asymptomatic.5 One series has described
anti‐PD‐1‐induced genital LP (in 2/10 patients with
oral reactions).5 Oesophageal LP is a rare manifestation
of idiopathic LP.6 Radiotherapy may trigger LP at ra-
diation sites and radiation may potentiate the autoim-
mune toxicity of nivolumab.1,3
This case demonstrates the management challenge
of systemic lichenoid reactions, in the context of ma-
lignancy. Cutaneous LP is usually managed with topical
treatment. Vulvovaginal, oesophageal and aural LP
often require systemic treatment, interruption of anti‐
PD‐1 therapy and intervention including endoscopic
dilatations.6
To our knowledge, oesophageal and aural LP have
not been reported in anti‐PD‐1‐induced LP. In patients
with cutaneous LP, involvement of widespread mucosal
sites should be considered.
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F I GUR E 1 (a) Apical erythema of the
gingiva. (b) Symmetrical tender erythema of
the labia. (c) A pruritic rash of the flank and
lower abdomen consisting of flat‐topped
purple papules
F I GUR E 2 (a) Skin biopsy from the
abdomen (�200 magnification) showed classic
features of lichenoid inflammation with
dyskeratotic keratinocytes and some
eosinophils (not shown) consistent with a
drug‐induced lichenoid reaction. (b) Skin
biopsy of the vulva (�200 magnification)
demonstrating parakeratosis, a dense
lichenoid lymphohistiocytic infiltrate, mild
basal degeneration and colloid bodies within
the epidermis, consistent with lichenoid
inflammation. (c) Oesophageal biopsy (�40
magnification) showing squamous mucosa with
chronic inflammation concentrated around
basal epithelium and Civatte body formation
consistent with lichen planus
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